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Introduction Verbal autopsy (VA) can be integrated 
into civil registration and vital statistics systems, but 
its accuracy in determining HIV-associated causes of 
death (CoD) is uncertain. We assessed the sensitivity and 
specificity of VA questions in determining HIV status and 
antiretroviral therapy (ART) initiation and compared HIV-
associated mortality fractions assigned by different VA 
interpretation methods.
Methods Using the WHO 2012 instrument with added ART 
questions, VA was conducted for deaths among adults with 
known HIV status (356 HIV positive and 103 HIV negative) 
in South Africa. CoD were assigned using physician-
certified VA (PCVA) and computer-coded VA (CCVA) 
methods and compared with documented HIV status.
results The sensitivity of VA questions in detecting HIV 
status and ART initiation was 84.3% (95% CI 80 to 88) and 
91.0% (95% CI 86 to 95); 283/356 (79.5%) HIV-positive 
individuals were assigned HIV-associated CoD by PCVA, 
166 (46.6%) by InterVA-4.03, 201 (56.5%) by InterVA-5, 
and 80 (22.5%) and 289 (81.2%) by SmartVA-Analyze 
V.1.1.1 and V.1.2.1. Agreement between PCVA and older 
CCVA methods was poor (chance-corrected concordance 
[CCC] <0; cause-specific mortality fraction [CSMF] 
accuracy ≤56%) but better between PCVA and updated 
methods (CCC 0.21–0.75; CSMF accuracy 65%–98%). 
All methods were specific (specificity 87% to 96%) in 
assigning HIV-associated CoD.
Conclusion All CCVA interpretation methods 
underestimated the HIV-associated mortality fraction 
compared with PCVA; InterVA-5 and SmartVA-Analyze 
V.1.2.1 performed better than earlier versions. Changes 
to VA methods and classification systems are needed to 
track progress towards targets for reducing HIV-associated 
mortality,
InTroduCTIon
The Joint United Nations Programme 
on HIV/AIDS (UNAIDS) aims to reduce 
the number of AIDS-related deaths from 
1.2 million to under 0.5 million by 2020.1 Most 
HIV-related deaths occur in low-income and 
middle-income countries (LMIC).2 Mortality 
data form the bedrock of health research 
and policy decision-making, but there are few 
direct estimates of overall or cause-specific 
mortality among people living with HIV in 
LMIC. Global estimates are generated using 
complex mathematical models and data from 
several sources, including civil registration 
and vital statistics (CRVS) systems, seroprev-
alence surveys, and antenatal and antiretro-
viral therapy (ART) programmes.3 The scar-
city of reliable mortality data will make it diffi-
cult to track progress towards the ambitious 
UNAIDS targets.
The direct estimation of HIV-associated 
mortality is challenging. Death certificates 
Key questions
What is already known?
 ► Verbal autopsy (VA) is proposed to be used more 
widely where civil registration and vital statistics 
systems are weak, but VA methods have not been 
validated against a quality reference standard for 
HIV-associated deaths.
What are the new findings?
 ► We used the leading VA interpretation methods to 
assign causes of death to adults with known HIV 
status in South Africa.
 ► Among HIV-positive adults, automated VA estimates 
of the HIV-associated mortality fraction were much 
lower than the probable true fraction, though a more 
recent version of SmartVA-Analyze (V.1.2.1) as-
signed a higher fraction.
 ► Automated VA interpretation is likely to result in un-
derestimation of HIV-associated mortality.
What do the new findings imply?
 ► The VA instrument could be enhanced by the ad-
dition of an HIV/tuberculosis module; modifications 
to classifications systems are needed to capture all 
deaths among HIV-positive people and to differen-
tiate deaths due to HIV-related immunosuppression 
from other causes.
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have poor accuracy, particularly in resource-limited 
settings,4 and HIV-related causes may be omitted from 
death certificates because of stigma.5–7 In countries 
without robust CRVS systems, estimates of cause-specific 
mortality are often derived, in part, from verbal autop-
sies (VAs), structured interviews with relatives or carers 
of deceased individuals, mostly conducted at health and 
demographic surveillance system (HDSS) sites.8 VA inter-
pretation methods assign causes of death (CoD) per 
International Statistical Classification of Diseases and 
Related Health Problems (ICD) rules. For demographic 
purposes, only a single ‘underlying’ CoD is assigned to 
each decedent; all HIV-associated deaths are thereby 
included under one of the five ICD categories, defined 
as, HIV disease resulting in (respectively) infectious and para-
sitic diseases (B20); malignant neoplasms (B21); other specified 
diseases (B22); other conditions (B23); or unspecified HIV 
disease (B24).9
The global roll-out of ART has already had an impact 
on all-cause mortality in areas of high HIV prevalence10 
and cause-specific patterns are certain to change as 
more people receive treatment, live longer, and die of 
causes other than HIV.11 Recent guidelines advocating 
ART for all people living with HIV will likely accelerate 
this process,12 but current systems do not allow for the 
enumeration of all deaths among HIV-positive individ-
uals, which is needed to differentiate between deaths due 
to HIV-related immunosuppression and other causes. 
While the WHO standardised VA instrument does ask 
about HIV status, it did not, until recently, ask about 
ART.13 VA has been used extensively in areas of high HIV 
prevalence, but has not been validated against a robust 
gold standard for HIV-related and tuberculosis (TB)-re-
lated deaths.14
Using data from South Africa, we aimed to estimate 
the sensitivity and specificity of existing WHO VA ques-
tions in detecting HIV status and of additional questions 
in detecting ART initiation, compared with a reference 
standard of confirmed HIV status and ART initiation 
from clinical and research data; to estimate the speci-
ficity of VA interpretation methods in assigning HIV-asso-
ciated CoD, compared with confirmed and VA-reported 
HIV status; and to compare the HIV-associated mortality 
fractions assigned to HIV-positive adults by different VA 
interpretation methods.
MeTHods
Parent studies
This study was nested within three large studies conducted 
in South Africa between 2012 and 2015. (1) ‘TB Fast 
Track’ was an open, cluster-randomised trial of empirical 
TB treatment in ambulatory adults with advanced HIV 
who were not on ART or TB treatment at the point of 
enrolment, conducted in 24 primary healthcare clinics 
(PHCs).15 (2) ‘XPHACTOR’ was an interventional 
cohort study investigating the use of Xpert MTB/RIF 
in a systematic sample of HIV-positive adults attending 
outpatient clinics for HIV care.16 (3) ‘XTEND’ was a clus-
ter-randomised trial evaluating the impact on mortality 
of Xpert MTB/RIF roll-out; it enrolled HIV-positive and 
HIV-negative adults who had sputum sent for TB investi-
gation at 40 PHCs.17
HIV-negative individuals
To estimate the specificity of the VA question ‘Was there 
any diagnosis of HIV/AIDS?’ in detecting HIV status, VAs 
were conducted among confirmed HIV-negative adults 
who died in any of the five general hospitals to which 
TB Fast Track participants were referred. Based on esti-
mated mortality in the three parent studies, 329 VAs were 
predicted among HIV-positive individuals; VA specificity 
in assigning HIV-associated deaths was predicted at 90% 
(based on a large study in Africa).18 A target was set of 121 
VAs in HIV-negative adults to achieve 95% confidence 
intervals (CI) of width ±5% around a point estimate of 
specificity of 90%.
Registers of inpatient deaths were reviewed at hospital 
mortuaries; all adults who died between June 2014 and 
October 2015 with a hospital-assigned CoD that was 
not explicitly HIV-associated, traumatic or maternal 
were included for further review. Inclusion was initially 
restricted to individuals aged 18–55 years to be similar 
in age to HIV-positive decedents, but, due to the small 
numbers of deaths among young people from causes 
other than those listed above, this was increased to 
18–70 years. The name, sex, dates of birth and death and 
hospital identifiers of each included adult were recorded; 
hospital files and the National Health Laboratory Service 
(NHLS) database were searched for HIV test results. The 
HIV test date and contact details of next-of-kin, where 
available, were recorded for those with a negative HIV 
test (rapid test or ELISA) in the 1 year prior to death and 
no evidence of a subsequent positive test. Relatives were 
contacted and a VA conducted per standard procedures 
outlined below.
data collection
VAs were conducted by trained lay-interviewers at the 
families’ homes or at other locations of their choosing, 
1–12 months after death. The WHO 2012 VA instrument 
was used,19 with questions added around ART and treat-
ment for TB (online Supplementary table 1); these ques-
tions were asked only to respondents who answered ‘Yes’ 
to ‘Was there any diagnosis of HIV/AIDS?’ or ‘Was there 
any diagnosis of tuberculosis?’, respectively. VA inter-
viewers were blinded to causes of death assigned by clini-
cians at health facilities (unless this was disclosed by the 
respondent during the VA interview).
Clinical data to confirm HIV status, ART initiation, TB 
diagnosis and TB treatment were obtained from clinic 
and hospital files, parent study databases and the NHLS 
online database. Data were available for all decedents 
regarding HIV status and for all HIV-positive decedents 
regarding ART initiation.
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data management and cause of death assignment
Quantitative VA data were entered directly into an online 
database (Mobenzi Technologies, Durban, South Africa) 
through a cell phone interface; narrative data were 
captured on paper. Data collected from hospital files and 
the NHLS database were entered into an EpiData V.3.1 
database (The EpiData Association, Odense, Denmark) 
and data from the parent studies into SQL databases 
(Bytes Technology Group, Johannesburg, South Africa). 
VA data were interpreted by both physician-certified VA 
(PCVA) and computer-coded VA (CCVA);
The PCVA method was based on WHO recommen-
dations, modified in line with changes made at the 
Medical Research Council/Wits University Agincourt 
HDSS site, South Africa (online Supplementary figure 
1). Two physicians, blinded to all other clinical informa-
tion, including information on ART obtained through 
VA, independently reviewed standard VA data and sepa-
rately assigned CoD using ICD-10 codes. Assigned CoD 
were compared and, where there were discrepancies, 
the cases were discussed by the two physicians, aiming 
for consensus. If a consensus could not be reached, a 
third, independent physician reviewed the data; if the 
CoD assigned by physician 3 matched that assigned by 
physicians 1 or 2, it was considered the final CoD. If no 
consensus was reached after review by three physicians, 
the individual was assigned an ‘indeterminate’ CoD. 
Mortality Medical Data System (MMDS) 2011 software 
(ftp:// ftp. cdc. gov/ pub/ Health_ Statistics/ NCHS/ Soft-
ware/ mmds/ 2011) was used to generate a single under-
lying CoD from multiple CoD assigned by PCVA.
For CCVA interpretation, VA data were mapped to 
InterVA input variables and fed into InterVA-4.03 and 
InterVA-5 (http://www. interva. net/), with the prev-
alence of malaria set to ‘low’ and HIV/AIDS to ‘high’. 
InterVA cause-specific mortality fractions (CSMFs) were 
generated by dividing the sum of the likelihoods of each 
cause category by the sum of likelihoods for all causes 
after the calculation of the residual indeterminate 
component, per the InterVA user guide20; estimations 
of specificity and individual agreement used the ‘mostly 
likely’ assigned cause for comparison. VA data were also 
mapped to the Population Health Metrics and Research 
Consortium (PHMRC) full instrument and fed into 
SmartVA-Analyze V.1.1.1 and V.1.2.1 (http://www. health-
data. org/ verbal- autopsy/ tools), with ‘Malaria region’ 
and ‘Free text’ deselected (all versions) and ‘HIV region’ 
selected (V.1.2.1 only). Narrative data were not provided 
to SmartVA-Analyze as they were captured on paper.
reference definitions
An individual was considered HIV positive if a positive 
result had been recorded and HIV negative if a negative 
result had been recorded in the 1 year prior to death 
without a subsequent positive result. An individual 
was considered to have initiated ART if this had been 
recorded in a clinic, hospital or research file; estimation 
of treatment adherence was not possible based on the 
data available. Self-report was not considered sufficient 
evidence of HIV status (positive or negative) or ART 
initiation. A death due to ICD-10 codes B20–B24 (PCVA; 
underlying cause), ‘HIV/AIDS’ (InterVA) or ‘AIDS’ 
(SmartVA-Analyze) was considered HIV-associated; a 
death from any other cause was considered non-HIV-as-
sociated.
statistical analysis
Individuals with unknown HIV status were excluded from 
all analyses (figure 1). For estimation of sensitivity and 
specificity, answers to VA questions of ‘Do not know’ were 
recoded as ‘No’, to match the methods used by InterVA 
and SmartVA-Analyze.21 22 The sensitivity and specificity 
of VA questions were calculated with exact binomial 
95% CI. The specificities of VA methods in assigning 
HIV-associated CoD were calculated compared with 
confirmed HIV status, as defined above, and VA-reported 
HIV status, to simulate situations in which clinical HIV 
data are not available.
Reference CoD were not available for all decedents 
and, because people with HIV may die from many 
causes, including those unrelated to HIV, sensitivity of 
VA methods in assigning CoD could not be estimated. 
Cohen’s kappa (Κ) and chance-corrected concordance 
(CCC) were used to measure individual-level agreement 
between VA methods; Lin’s concordance correlation 
coefficient (ρC), CSMF accuracy, and chance-corrected 
CSMF accuracy were used to measure population-level 
agreement based on two possible CoD: HIV-associ-
ated and non-HIV-associated, as defined above. In the 
absence of a clinical reference standard, CCVA CoD were 
compared with PCVA CoD. All analyses were conducted 
using Stata V.14. Figure 2 was developed using eulerAPE23 
and Inkscape (https:// inkscape. org) software.
ethical considerations
This substudy was approved by the human research ethics 
committees of the London School of Hygiene & Tropical 
Medicine and the University of the Witwatersrand. All 
decedents were assigned numeric identities to ensure 
anonymity during collection of clinical data and all VA 
respondents gave written informed consent for interview.
role of the funding source
The funders had no role in the design of the study; in 
the collection, analysis, and interpretation of data; in the 
writing of the report; or in the decision to submit the 
paper for publication.
resulTs
demographics
A total of 986 VAs were attempted; 491 (49.8%) were 
successfully completed (figure 1). Individuals with 
unknown HIV status (n=32) were excluded from the 
analysis. VA data from 459 individuals were included, 
356 (77.6%) HIV positive and 103 (22.4%) HIV nega-
tive (table 1); 240 (52.3%) decedents were female and 
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the median age was 41.5 (IQR 34–52) years. Demo-
graphics are described in table 1; comparison between 
HIV-positive and HIV-negative individuals showed impor-
tant differences only in median age (39.6 vs 52.1 years; 
p<0.001).
sensitivity and specificity of VA questions
The VA question, ‘Was there any diagnosis of HIV/
AIDS?’ correctly identified 300/356 HIV-positive individ-
uals and incorrectly identified 6/103 HIV-negative indi-
viduals as HIV positive (sensitivity 84.3% [95% CI 80 to 
88]; specificity 94.2% [95% CI 88 to 98]; table 2). The 
question ‘Did the deceased ever take ART?’, added to 
the WHO VA instrument, was asked to the 306 respond-
ents who answered ‘Yes’ to the HIV diagnosis question: 
193/212 individuals who had initiated ART were correctly 
reported as having done so, but the question was also 
answered ‘Yes’ for 44/94 individuals who had not initi-
ated ART (sensitivity 91.0% [95% CI 87 to 95]; specificity 
53.2% [95% CI 43 to 64]).
ArT initiation dates
Dates of ART initiation were available from both VA 
interviews and clinical records for 125 individuals. The 
median difference between dates obtained from the 
two sources was 29 (IQR 11–111) days; 90/125 (72.0%) 
and 108/125 (86.4%) ART initiation dates from VA 
interviews were within 90 days and 1 year, respectively, 
of the dates in clinical records. Of the 237 individuals 
who were reported, at VA, to have been taking ART, 36 
(15.1%) were reported not to have been taking it at 
death and 62 (26.2%) not to have been taking it every 
day.
Performance of VA interpretation methods
Estimating HIV-associated mortality among HIV-positive adults
Of 356 HIV-positive adults, 283 (79.5%) were assigned 
an HIV-associated CoD by PCVA; 166 (46.6% as ‘most 
likely’ cause; CSMF 44.7% when all assigned CoD and 
associated likelihoods included) by InterVA-4.03; 201 
(56.5%; CSMF 54.5%) by InterVA-5; 80 (22.5%) by 
SmartVA-Analyze V.1.1.1; and 289 (81.2%) by Smart-
VA-Analyze V.1.2.1 (table 3 and figure 2). These 
proportions were higher among the 300 individ-
uals reported HIV positive at VA (255 [85%] PCVA; 
150 [50%; CSMF 48%] and 178 [59%; CSMF 57%] 
InterVA-4.03 and InterVA-5; and 69 [23%] and 285 
[95%] SmartVA-Analyze V.1.1.1 and V.1.2.1). Individ-
ual-level and population-level agreement was poor 
between PCVA/InterVA-4.03 and PCVA/SmartVA-Ana-
lyze V.1.1.1 (CCC<0; CSMF accuracy ≤56%); agree-
ment was better between PCVA and newer versions 
of InterVA and SmartVA-Analyze (CCC 0.21 and 0.75; 
CSMF accuracy 65% and 98%; table 3).
Specificity in assigning HIV-associated CoD
Among all 459 individuals, PCVA assigned 287 (63%) 
HIV-associated CoD, compared with 177 (39%; CSMF 37%) 
by InterVA-4.03, 214 (47%; CSMF 45%) by InterVA-5, and 
Figure 1 Flow diagram showing numbers enrolled into each of the parent studies*, subsequent deaths, number of VAs 
completed and numbers of confirmed HIV-positive and HIV-negative individuals included in final analysis. *TB Fast Track and 
XPHACTOR enrolled only HIV-positive adults; XTEND enrolled HIV-positive and HIV-negative adults being investigated for TB. 
†VA was attempted but could not be completed. TB, tuberculosis; VA, verbal autopsy.
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85 (19%) and 294 (64%) by SmartVA-Analyze V.1.1.1 and 
V.1.2.1, respectively (table 4). Compared with confirmed 
HIV status, the specificity of PCVA was 96.1% (95% CI 90 to 
99); specificities of CCVA methods were 89.3% (95% CI 82 
to 95), 87.4 (95% CI 79 to 93), 95.1% (95% CI 89 to 98), and 
95.1% (95% CI 89 to 98) for InterVA-4.03, InterVA-5, and 
SmartVA-Analyze V.1.1.1 and V.1.2.1, respectively. Specif-
icities of all methods, except SmartVA-Analyze V.1.2.1, 
Figure 2 Euler diagram illustrating the number of confirmed HIV-positive individuals assigned HIV-associated CoD by the five 
VA methods and overlap between methods, using SmartVA-Analyze V.1.1.1 and InterVA-4 (left) and SmartVA-Analyze V.1.2.1 
and InterVA-5 (right; n, [%/356]). CoD, cause of death; PCVA, physician-certified verbal autopsy; VA: verbal autopsy.
Table 1 Demographics for all decedents, stratified by confirmed HIV status (n=459)
Characteristic
All with confirmed HIV 
status (n=459), n (%) or 
median (IQR)
Confirmed HIV positive 
(n=356), n (%) or 
median (IQR)
Confirmed 
HIV negative (n=103), n 
(%) or median (IQR) P values*
Female 240 (52.3) 195 (54.8) 45 (43.7) 0.05
Age at death, years 41.5 (33.6 to 51.5) 39.6 (33.0 to 47.4) 52.2 (42.4 to 60.9) <0.001
Black African 457 (99.6) 354 (99.4) 103 (100) 0.45
South African national 433 (94.3) 336 (94.4) 97 (94.2) 0.94
Enrolled or hospitalised in 
periurban area†
330 (71.9) 253 (71.1) 77 (74.8) 0.46
Initiated ART after enrolment‡ 117 (25.5) 117 (32.9) NA –
Time from
  Enrolment‡ to death, days 80.5 (35 to 161) (n=356) 80.5 (35 to 161) NA – 
  HIV-negative test to death, days 14 (5 to 59) (n=103) NA 14 (5–59) – 
  Death to VA, days 218.5 (106 to 325) 235 (102 to 338) 174 (110 to 271) 0.04
*Kruskal-Wallis or Χ2 test, as appropriate.
†Site of enrolment for individuals enrolled to one of the three parent studies; site of hospitalisation for HIV-negative individuals recruited from 
hospitals.
‡Enrolment into parent study.
ART, antiretroviral therapy; VA, verbal autopsy.
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which increased to 97%, were lower when compared with 
VA-reported HIV status, at 81%, 78%, 83%, and 90% 
for PCVA, InterVA-4.03, InterVA-5, and SmartVA-Ana-
lyzeV.1.1.1, respectively (table 4).
dIsCussIon
The VA question about HIV diagnosis showed moderate 
to high sensitivity and specificity in correctly identifying 
HIV status. Added questions around ART initiation were 
also sensitive and a high proportion of VA ART initiation 
dates were within 3 months of the confirmed date from 
clinical records. VA interpretation methods differed 
widely in their estimation of the HIV-associated mortality 
fraction among confirmed HIV-positive individuals; 
CCVA methods used until 2016 gave estimates that were 
likely much lower than the true fraction. All VA inter-
pretation methods showed high specificity in assigning 
HIV-associated CoD.
estimating HIV prevalence and ArT initiation
The moderate-to-high sensitivity and specificity of the HIV 
question in detecting HIV status seen here and in a study 
conducted in Malawi (sensitivity 83%, specificity 98%)24 
suggests that VA may be useful in generating estimates of 
HIV prevalence among deceased individuals. However, 
sensitivity was lower when tested in a larger, more diverse 
population: a study conducted across five sub-Saharan 
African countries from 1990 to 2011 focused primarily 
on estimating the specificity of InterVA-4 in diagnosing 
HIV-associated CoD18; crude estimates of sensitivity 
and specificity of the VA instrument in detecting HIV 
status can, however, be derived from the data presented 
(sensitivity 33.7% [95% CI 32 to 36], specificity 93.6% 
[95% CI 93 to 95]). Differences in estimates of sensi-
tivity may be attributable to increased availability of 
testing and reduced stigma over time, particularly as the 
multicountry study analysed deaths that occurred over a 
20-year period18; in the Malawian study, the proportion of 
respondents reporting knowledge of HIV status increased 
from 48% in 2003/2004 (n=300) to 99% in 2013/2014 
(n=303).24 The consistently high specificity suggests that 
VA is unlikely to overestimate HIV prevalence in high 
prevalence settings; further evaluations of the VA ques-
tion are needed, including reanalysis of existing raw VA 
data from HDSS sites, to assess better its suitability for 
estimating HIV prevalence in different contexts.
The only other study to have evaluated VA for ART 
use estimated sensitivity and specificity at 92% and 46%, 
respectively (Malawi, 2009–2014, n=154).24 The low spec-
ificity seen also in our study suggests a need to further 
refine questions around ART; HIV-positive individuals 
are often prescribed several different drugs and confu-
sion among VA respondents is understandable. Inclu-
sion of variants of these questions in future VA validation 
studies is recommended.
estimating HIV-associated mortality
The high specificity of PCVA and InterVA in assigning 
HIV-associated CoD is consistent with previous evalu-
ations in settings with high HIV prevalence. The speci-
ficity of PCVA has been between 89% and 99% in studies 
conducted in Uganda,25 Tanzania,26 and Malawi,27 and 
InterVA-4 has been reported as 76%–90% specific in 
studies in several African countries.18 27 28 No similar eval-
uations of SmartVA-Analyze were found in the literature.
The consistently high specificity of VA interpretation 
methods suggest that they are unlikely to overestimate 
HIV-associated mortality. Estimating the sensitivity of 
a VA method, however, is challenging even when high-
quality data are available, given the inherent uncertainty 
involved in assigning CoD. Only one study, conducted 
by our group in South Africa, has compared VA to CoD 
derived from pathological autopsy in HIV-positive indi-
viduals and found that VA methods likely underestimated 
HIV-associated CoD.29 In part because of difficulties faced 
with ICD coding, there are few direct (autopsy or clinical) 
estimates of the HIV-associated mortality fraction among 
HIV-positive adults. A recent systematic review, which 
included only studies of HIV-positive individuals entirely 
or mostly on ART (n=19 studies), estimated that 18.5% 
Table 4 Number assigned (n=459) and specificity of VA methods in assigning HIV-associated causes of death, compared 
with confirmed (n=103) and VA-reported (n=153) HIV status
VA method
Number assigned an HIV-
associated CoD, n (CSMF; 
%/459)
Specificity of VA method
Based on confirmed 
serostatus (95% CI)*
Based on VA-reported HIV 
status (95% CI)†
PCVA 287 (62.5) 96.1 (90.4 to 98.9) 81.0 (73.9 to 86.9)
InterVA-4.03‡ (37.1) 89.3 (81.7 to 94.5)§ 83.0 (76.1 to 88.6)§
InterVA-5‡ (44.9) 87.4 (79.4 to 93.1)§ 78.4 (71.1 to 84.7)§
SmartVA-Analyze V.1.1.1 85 (18.5) 95.1 (89.0 to 98.4) 90.2 (84.3 to 94.4)
SmartVA-Analyze V.1.2.1 294 (64.1) 95.1 (89.0 to 98.4) 97.4 (93.4 to 99.3)
*n=103 individuals confirmed HIV negative.
†n=153 individuals reported HIV negative or with HIV status unknown.
‡InterVA-4 and InterVA-5 CSMFs calculated from all assigned CoD with associated likelihoods.
§Individuals considered ‘test positive’ if HIV/AIDS assigned as most likely CoD (n=177 for InterVA-4; n=214 for InterVA-5).
CoD, cause of death; CSMF, cause-specific mortality fraction; PCVA, physician-certified verbal autopsy; VA, verbal autopsy.
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(95% CI 13 to 24) of deaths in HIV-positive individuals 
on ART in sub-Saharan countries were due to ‘non-AIDS’ 
causes (ie, 76%–83% due to AIDS).11 This review, however, 
treated deaths due to ART toxicity as ‘non-AIDS’, which 
is contrary to WHO guidance30 and means that overall 
HIV-associated mortality may have been underestimated. 
In populations containing fewer individuals on ART, 
the HIV-associated mortality fraction is likely to be even 
higher, as seen in several pathological autopsy studies.31 
In our study, only PCVA and SmartVA-Analyze V.1.2.1 esti-
mated an HIV-associated mortality fraction close to the 
figure above (80% and 85%). InterVA-4.03, InterVA-5, 
and SmartVA-Analyze V.1.1.1 estimated smaller HIV-as-
sociated mortality fractions (45%, 55%, and 23%); as a 
high number of individuals in our study had not initiated 
ART, these estimates are likely lower than the true HIV-as-
sociated mortality fraction in this population.
Plans are underway to integrate VA into CRVS systems,32 
a proposal made feasible, in part, by the increased effi-
ciency of CCVA methods. VA has been previously used 
mainly at HDSS sites, where, through trend analysis, 
systematic errors in estimates could be detected and 
adjusted for. If used to supplement CRVS data, however, 
VA findings may directly influence policy and health 
planning decisions and will need to be more stringently 
validated for key causes of mortality such as HIV.
In our study, SmartVA-Analyze V.1.2.1 assigned a much 
higher HIV-associated mortality fraction than V.1.1.1, 
though the reason for the change and the effect of this on 
assigning other causes is not clear, as code for the software 
is not available. It may be that the newer version is guided 
by reported HIV status: V.1.2.1 assigned an HIV-associ-
ated cause to 95% of individuals reported HIV-positive in 
the VA interview, compared with 23% assigned by V.1.1.1 
(data not shown). None of the VA methods evaluated 
here was provided with data on ART use; simply assigning 
an HIV-associated cause to all HIV-positive individuals is 
unlikely to be a viable long-term strategy in areas with high 
ART coverage. Nevertheless, both older CCVA methods 
likely allocate insufficient weight to the question about 
HIV diagnosis, which has now been shown to be sensitive 
and specific in Malawian24 and South African contexts. 
InterVA assigns CoD based on a probabilistic algorithm, 
which weights questions per the recommendations of a 
panel of expert physicians, convened in 2006 and 2011.33 
In our study, physicians reviewing VA data gave the HIV 
question high importance, assigning an HIV-associated 
CoD to 84% of the 306 individuals reported HIV-posi-
tive and to 52% of the 42 individuals where the respon-
dent answered, ‘Do not know’ (compared with 49% and 
24% by InterVA-4.03; 59% and 33% by InterVA-5; 23% 
and 21% by SmartVA-Analyze V.1.1.1; and 95% and 7% 
by SmartVA-Analyze V.1.2.1 [n=459; data not shown]). 
In part, this is likely because all ‘Do not know’ answers 
are converted to ‘No’ by these CCVA methods. Along 
with adjustments to weighting, an ability to differentiate 
between the two answers may be needed in the interpre-
tation of key questions such as this.
limitations and strengths
All individuals included in this analysis were recruited 
from health facilities (clinics or hospitals) and around 
76% died in hospitals (data not shown). This is higher 
than the proportion of facility-based deaths in South 
Africa (43% in hospital, 23% at home, 23% in unknown 
locations in 2016)34 and likely in many other countries 
in sub-Saharan Africa (though these data are not avail-
able due to the absence of robust CRVS systems in most 
of these countries).7 This may have led to overestima-
tion of the sensitivity and specificity of questions around 
HIV diagnosis and ART, as families of individuals who 
received medical care prior to death are more likely to 
be familiar with medical terminology.35 In addition, 72% 
of individuals were enrolled or died in urban areas; this 
limits the generalisability of our findings to more rural 
parts of South Africa or other countries in sub-Saharan 
Africa, which have larger rural populations (an estimated 
62% of people in the WHO AFRO region were living in 
rural areas in 2013).36 However, the high sensitivity and 
specificity of the VA HIV question in the Malawian study 
cited above, which was conducted in an HDSS site,24 and 
the only slight-to-moderate reductions, in our study, in 
the sensitivity and specificity of VA questions and VA 
methods (specificity only) in rural versus urban settings 
(online Supplementary tables 2–4), suggest that these 
questions and methods may perform similarly in other 
sub-Saharan African settings, though further evaluation 
is needed.
The relatively low number of HIV-negative individuals 
reduced the accuracy of specificity estimates and, despite 
best efforts, the HIV-positive and HIV-negative groups 
were not age matched. HIV is generally less likely to 
be considered as a CoD in older individuals37 (though 
recent data from South Africa suggest this may no longer 
be appropriate)38; the higher median age of HIV-nega-
tive decedents may have led to overestimation of specific-
ities in detecting HIV status and assigning HIV-associated 
CoD. Estimates of sensitivity, however, should not have 
been affected. Physicians assigning CoD were aware that 
decedents were likely to have been enrolled in studies 
of HIV/TB and this may have led to their assigning 
higher numbers of HIV-associated CoD; VA interviewers 
were aware of a decedent’s HIV status before the VA was 
conducted, and this may have affected the way questions 
around HIV and ART were asked or interpreted during 
the interview. The most recent WHO VA instrument39 
was not used for data collection and SmartVA-Analyze 
was not provided with narrative data, which may have led 
to suboptimal performance of the software, although the 
omission of these data will likely have had minimal effect, 
as the software does not consider the phrases ‘HIV’ or 
‘AIDS’ as ‘words of interest’.22 Clinical reference CoD 
were not available for all decedents and the sensitivity of 
VA methods in assigning HIV-associated CoD could not 
be assessed.
This study’s strengths include having confirmed HIV 
status for all decedents included in the analysis; the 
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median time from HIV-negative test to death being 
2 weeks, with 75% of HIV-negative individuals tested 
less than 2 months before death; and using the leading 
VA interpretation methods, including the most recent 
versions of SmartVA-Analyze and InterVA, to estimate 
the HIV-associated mortality fraction among HIV-positive 
individuals, something not previously done in VA studies.
next steps
The UNAIDS goal of less than 0.5 million HIV-related 
deaths by 2020 calls for an absolute reduction in events,1 
which will require methods to identify HIV-associated 
deaths more accurately.14 40 Classification systems require 
alterations that will allow for the identification of all deaths 
in people with HIV and prediction of possible changes 
in mortality patterns through increased availability of 
ART; a flexible system, with shorter or partial revision 
cycles, would allow for more adaptability in the face of an 
evolving epidemic. In the short term, other methods may 
provide useful data for monitoring changes in mortality 
patterns: a recent study from Mozambique found good 
agreement between CoD assigned by minimally invasive 
autopsy (MIA) and complete autopsy.41 42 These findings, 
along with previous evaluations of MIA,43–45 suggest it 
may be useful in providing more accurate CoD data as an 
adjunct to surveillance at sentinel sites in LMIC.
ConClusIons
VA interpretation methods differed in their estimates of 
HIV-associated mortality and older CCVA methods under-
estimated the HIV-associated mortality fraction; estimates 
from PCVA and revised CCVA methods were closer to the 
probable true fraction. VA questions were sensitive and 
specific in detecting HIV status and sensitive in detecting 
ART initiation. The addition of an HIV/TB module to 
the VA instrument is recommended; future VA validation 
studies should be used to trial questions prior to inclu-
sion in the standardised VA instrument. Modifications 
to classification systems are needed to capture all deaths 
among HIV-positive people and differentiate deaths due 
to HIV-related immunosuppression from other causes; 
closely aligned is a need for more accurate direct esti-
mates of HIV-associated mortality to track progress 
towards goals set by UNAIDS.
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